| SEEL:Seelos Therapeutics Inc * | | Charting | News | Options |
*Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements |
||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
1.04% $0.00
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose) |
|
| PR Newswire |
|
Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided an update on top-line data of the Phase 2/3 HEALEY ALS Platform trial. This study was performed in collaboration with The Sean M. Healey and AMG Center, which is viewed as an influential force in ALS research and in caring for the ALS community. Their unique and innovative approach continues to be a benefit to the ALS community and its contributions have helped bring the last two FDA approved therapies for ALS to market. |
| Full Story → |
|
| Headline News |
|
| Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules |
| 8:30a ET January 26 '24 PR Newswire |
|
|
| How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition |
| 9:01a ET January 24 '24 PR Newswire Europe |
|
|
| How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition |
| 9:01a ET January 24 '24 PR Newswire |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| April 19 '24. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, April 18 '24. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
